检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Thomas Pabst,Cristina Papayannidis,Fatih Demirkan,Vadim Doronin, Laura M Fogliatto,Christina Guttke,Emmanuel Gyan,Nada Hamad,Pilar Herrera,Anna Hultberg,Julie Jacobs,Amy J Johnson,Angélique Langlois,Xuewen Ma,Giovanni Martinelli,Montserrat Arnan,Rouven Müller,Kerri Nottage,Yishai Ofran,Muhit Özcan

The Lancet Haematology（2023）

引用 1|浏览15
暂无评分
摘要
Janssen Research & Development and argenx.
更多
查看译文
关键词
acute myeloid leukaemia,intensive chemotherapy,azacitidine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要